Tilavonemab (ABBV-8E12)

Tilavonemab (ABBV-8E12)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Tilavonemab (ABBV-8E12)</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>Primary Pathology</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>Aβ → tau pathology</td>
</tr>
<tr>
<td class="label">Progressive Supranuclear Palsy</td>
<td>4R tau</td>
</tr>
<tr>
<td class="label">Corticobasal Degeneration</td>
<td>4R tau</td>
</tr>
<tr>
<td class="label">Chronic Traumatic Encephalopathy</td>
<td>3R/4R tau</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Epitope</td>
</tr>
<tr>
<td class="label">Tilavonemab (ABBV-8E12)</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Gosuranemab (BIIB080)</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Mid-region</td>
</tr>
<tr>
<td class="label">JNJ-63742057</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Lu AF87908</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ABBV-8E12 (Tilavonemab)</td>
<td>mAb</td>
</tr>
<tr>
<td class="label">ABBV-951</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">Various</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Epitope</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Go

Tilavonemab (ABBV-8E12)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Tilavonemab (ABBV-8E12)</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>Primary Pathology</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>Aβ → tau pathology</td>
</tr>
<tr>
<td class="label">Progressive Supranuclear Palsy</td>
<td>4R tau</td>
</tr>
<tr>
<td class="label">Corticobasal Degeneration</td>
<td>4R tau</td>
</tr>
<tr>
<td class="label">Chronic Traumatic Encephalopathy</td>
<td>3R/4R tau</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Epitope</td>
</tr>
<tr>
<td class="label">Tilavonemab (ABBV-8E12)</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Gosuranemab (BIIB080)</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Mid-region</td>
</tr>
<tr>
<td class="label">JNJ-63742057</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Lu AF87908</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ABBV-8E12 (Tilavonemab)</td>
<td>mAb</td>
</tr>
<tr>
<td class="label">ABBV-951</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">Various</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Epitope</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>N-terminal</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Mid-region</td>
</tr>
<tr>
<td class="label">Zagotenemab</td>
<td>MC1</td>
</tr>
</table>

Tilavonemab (development code ABBV-8E12) is a humanized anti-tau monoclonal antibody developed by AbbVie for the treatment of Alzheimer's disease and progressive supranuclear palsy (PSP)[@tilavonemab2021][@tilavonemab2023]. It represents one of the most advanced attempts to target pathological tau protein through immunotherapy. Despite promising preclinical data and early clinical results, the program was ultimately discontinued following negative Phase II trial results.

The development of tilavonemab provides important insights into the challenges of targeting tau pathology in neurodegenerative diseases. The antibody's mechanism, targeting the N-terminus of tau, was based on the hypothesis that blocking extracellular tau propagation could slow or halt disease progression. While this approach was scientifically rational, the clinical trials revealed complexities that remain incompletely understood.

Mechanism of Action

Tilavonemab was designed to target pathological tau species through a specific mechanism[@anti_tau_immunotherapy][@nterminal_tau]:

Target Epitope

N-Terminal Tau Binding:

• The antibody binds to the N-terminal region of human tau protein
• This region is exposed in pathological tau aggregates
• Does not bind to normal, functional tau in the same way
• Selectivity for aggregated over monomeric tau

Tau Clearance Mechanisms

Antibody-Mediated Clearance:

• Binding to extracellular tau marks it for removal
• Facilitates uptake by microglia via Fc receptor-mediated phagocytosis
• May promote degradation through lysosomal pathways
• Prevents cellular uptake and intercellular transmission

Tau Propagation Hypothesis

The therapeutic rationale rested on the prion-like propagation hypothesis[@tau_propagation]:

By neutralizing extracellular tau, the antibody was intended to break this propagation cycle.

Tau Biology and Target Rationale

Tau Protein in Neurodegeneration

Tau is a microtubule-associated protein that plays essential roles in neuronal function[@tau_biology]:

Normal Function:

• Stabilizes microtubules in axons
• Regulates axonal transport
• Modulates synaptic function

• Hyperphosphorylation leads to misfolding
• Aggregation into paired helical filaments (PHFs)
• Formation of neurofibrillary tangles (NFTs)
• Loss of normal function

Tauopathies

Tau pathology is characteristic of multiple neurodegenerative diseases:

Rationale for N-Terminal Targeting

The N-terminal approach was selected because:

Clinical Development

Phase I Study

The first-in-human study evaluated tilavonemab in both healthy volunteers and patients with early Alzheimer's disease[@phase]:

Design:

• Single and multiple ascending dose cohorts
• Dose range exploration
• Safety and pharmacokinetic assessment
• Biomarker evaluation including CSF tau

• Well-tolerated at all doses tested
• Showed dose-proportional pharmacokinetics
• Achieved target engagement in CSF
• Supported advancement to Phase II

Phase II Trial in Progressive Supranuclear Palsy

PSP is a pure tauopathy characterized by 4-repeat tau aggregates, making it an ideal testbed for anti-tau therapy[@tilavonemab2021]:

Study Design (NCT02880991):

• Randomized, double-blind, placebo-controlled
• Patients with probable Richardson's syndrome PSP
• Primary endpoint: Change in PSP Rating Scale (PSPRS)
• Secondary endpoints: Clinical measures, biomarker endpoints

• Did not meet primary efficacy endpoint
• Treatment generally well-tolerated
• No significant slowing of clinical decline
• Development for PSP discontinued

Phase II Trial in Alzheimer's Disease

The Alzheimer's disease trial represented the larger commercial opportunity[@tilavonemab2023]:

Study Design:

• Patients with early AD (MCI due to AD or mild AD dementia)
• Tau PET positivity required
• Multiple dose arms
• Primary clinical endpoints

• Did not meet primary efficacy endpoints
• No significant clinical benefit observed
• Generally consistent with PSP results
• Further development discontinued

Autopsy Case Study

An important finding came from an autopsy case of a PSP patient who received tilavonemab[@autopsy2022]:

Findings:

• Demonstrated antibody presence in brain tissue
• Evidence of interaction with tau pathology
• Showed expected mechanism of action at the tissue level
• Confirmed target engagement

• Antibody reached target in brain
• Bound to pathological tau species
• Supported mechanism of action
• Did not translate to clinical benefit

Biomarker Development

Tau PET Imaging

The clinical trials employed advanced tau PET imaging:

Tracers Used:

• [^18F]flortaucipir (AV-1451): Primary tau PET tracer
• Other tau tracers for validation

• Baseline tau burden
• Change in tau PET signal over time
• Regional distribution of tau pathology
• Correlation with clinical measures

• Tracer binding to off-target regions
• Limited sensitivity to early tau changes
• Interpretation of signal changes

CSF Biomarkers

Cerebrospinal fluid biomarkers provided complementary information:

Measures:

• Total tau (t-tau)
• Phosphorylated tau (p-tau181)
• Tau oligomers
• Neurodegeneration markers

• Variable effects on CSF tau species
• Target engagement demonstrated
• Biomarker changes did not predict clinical benefit

Post-Trial Learnings

What the Trials Taught Us

The discontinuation of tilavonemab and similar programs has yielded important insights:

Mechanism Limitations:

• Tau propagation may be downstream of the primary pathological process
• Antibody may be unable to reach sufficient brain concentrations
• N-terminal targeting may miss important pathological tau forms

• Patient selection may be critical
• Earlier intervention may be necessary
• Biomarkers may not accurately predict clinical response

• Multiple tau strains may require different approaches
• Interaction with amyloid pathology may be necessary
• Single-target approaches may be insufficient

Comparison with Other Anti-Tau Approaches

Most anti-tau antibody programs have failed to demonstrate clinical efficacy, highlighting the significant challenges in this therapeutic approach.

Pharmacological Considerations

Antibody Properties

Tilavonemab is a humanized monoclonal antibody with specific properties:

Structure:

• IgG1 backbone for optimal Fc-mediated effector functions
• Humanized variable regions to minimize immunogenicity
• Designed for optimal brain penetration

• Long half-life enabling monthly or less frequent dosing
• Dose-proportional exposure
• CSF penetration sufficient for target engagement

Dose Selection

The Phase II trials used doses selected based on:

• Preclinical efficacy models
• Target engagement biomarkers
• Safety margins identified in Phase I
• Modeling of brain exposure

Future Directions in Tau Immunotherapy

Lessons Applied to Next Generation Programs

Despite the failures, anti-tau immunotherapy remains an active area of research:

Target Selection:

• Exploring different epitopes (mid-region, C-terminal)
• Bispecific antibodies targeting multiple sites
• Combination approaches with anti-amyloid therapy

• Enhanced brain penetration approaches
• Active transport mechanisms
• Alternative administration routes

• Earlier disease stages
• Biomarker-defined populations
• Genetic risk factors

Alternative Approaches

Beyond antibodies, other tau-targeted strategies include:

Small Molecules:

• Tau aggregation inhibitors
• Tau acetylation modulators
• Microtubule stabilizers

• Antisense oligonucleotides
• siRNA approaches
• Gene editing

• Tau-targeting vaccines
• Engineered protein degraders

Current Status

Tilavonemab (ABBV-8E12) development has been discontinued following negative Phase II results in both Alzheimer's disease and PSP. The program provided important learnings about:

• Challenges of targeting tau with monoclonal antibodies
• N-terminal tau targeting approach limitations
• Biomarker engagement versus clinical efficacy
• The need for combination approaches
• Potential importance of earlier intervention

See Also

• [Tau Immunotherapy](/therapeutics/anti-tau-immunotherapy-programs)
• [Tau Protein](/proteins/tau)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Tauopathies](/diseases/tauopathies)
• [Gosuranemab](/therapeutics/gosuranemab)
• [Semorinemab](/therapeutics/semorinemab)

AbbVie: Company Profile

Background

AbbVie Inc. is a major American pharmaceutical company headquartered in North Chicago, Illinois, spun off from Abbott Laboratories in 2013. The company has a significant focus on immunology, oncology, neuroscience, and virology. AbbVie's neuroscience division has pursued therapeutics for Alzheimer's disease, Parkinson's disease, and other neurological conditions.

Tilavonemab Development History

Tilavonemab (ABBV-8E12) was discovered and developed through AbbVie's biologics research program:

• Origin: Humanized antibody derived from murine precursor
• Target: N-terminal region of tau protein
• Rationale: Block extracellular tau propagation
• Acquisition: Developed internally, not acquired from another company

AbbVie's Tau Pipeline

Beyond tilavonemab, AbbVie has pursued multiple tau-targeted approaches:

The discontinuation of tilavonemab represents a significant setback for AbbVie's neuroscience pipeline, but the company continues to invest in neurodegenerative disease research.

Detailed Trial Results Analysis

PSP Phase II (NCT02880991) Deep Dive

The Phase II trial in PSP enrolled patients at multiple international sites:

Patient Characteristics:

• Age: 60-85 years
• Diagnosis: Probable Richardson's syndrome PSP
• Disease duration: ≤5 years
• MMSE: ≥24
• Able to walk independently or with minimal assistance

• Primary endpoint (PSPRS change): No significant difference vs placebo
• Secondary endpoints: Mixed results
• Biomarker endpoints: Showed target engagement but no clinical correlation

Alzheimer's Disease Phase II Deep Dive

The AD trial was larger and more commercially significant:

Design Features:

• Enriched population: Tau PET positive required
• Early disease: MCI due to AD or mild AD dementia
• 52-week treatment duration
• Multiple dose cohorts

• Primary clinical endpoints not met
• No dose-response relationship observed
• Biomarker changes observed but not clinically meaningful
• Safety profile consistent with Phase I

Failure Mode Analysis

Why Did Tilavonemab Fail?

Multiple factors contributed to the lack of clinical efficacy:

1. Target Access Limitations

• Antibody brain penetration is inherently limited (~0.1-0.5% of plasma levels)
• Even with target engagement, may not achieve sufficient CNS concentrations
• Extracellular tau represents small fraction of total tau burden

• N-terminal targeting may not capture most pathological tau species
• Mid-region and C-terminal tau may be more aggregation-prone
• N-terminal antibodies may bind normal tau more than anticipated

• Patients had established pathology by trial entry
• Neurodegeneration may be too advanced for reversal
• Earlier intervention might be necessary for efficacy

• Multiple tau conformational variants exist
• Single antibody may not neutralize all strains
• Disease-specific strains may require targeted approaches

• Tau propagation may be downstream of primary driver
• Blocking propagation alone may not slow existing degeneration
• May need combination approaches targeting multiple pathways

Comparison with Similar Failures

The pattern of failures suggests fundamental issues with the antibody approach to tau targeting.

Lessons for Future Development

What Should Have Been Done Differently?

Based on tilavonemab learnings:

1. Earlier Intervention

• Treat patients before extensive neurodegeneration
• Consider prevention trials in genetic at-risk populations
• Monitor biomarker-positive pre-symptomatic subjects

• Require tau PET positivity for all trials
• Consider genetic stratification (MAPT mutations)
• Exclude rapidly progressing patients

• Pair with anti-amyloid therapy
• Target multiple tau epitopes simultaneously
• Consider microtubule stabilization

• Engineer antibodies for better brain penetration
• Explore intrathecal administration
• Use Trojan horse approaches

Implications for the Field

The tilavonemab failure has influenced industry strategy:

• Shift toward mid-region and MTBR targeting
• Increased interest in ASO and gene therapy approaches
• Greater emphasis on early intervention
• Focus on combination therapies

Competitive Landscape

N-Terminal Antibody Failures

The failure of tilavonemab joins similar programs:

Gosuranemab (Biogen):

• Same target epitope (N-terminal)
• Also failed in Phase II
• Highlighted consistent class effect issues

• Different epitope (MC1 conformational)
• Also failed to meet endpoints
• Suggests broader platform challenges

Industry Consolidation

These failures have led to:

• Reduced investment in anti-tau antibodies
• Shift to alternative modalities
• Consolidation of programs through partnerships

Current Status and Conclusion

Program Termination

AbbVie officially discontinued tilavonemab development following:

• Negative PSP Phase II results (2021)
• Negative AD Phase II results (2023)
• Assessment that further development was not viable

Legacy Value

Despite failure, the program contributed:

• Validation of antibody brain penetration
• Understanding of tau PET as biomarker
• Clinical data on tau-targeted approaches
• Foundation for future programs

Future Directions

AbbVie continues to pursue neurodegenerative disease therapeutics through alternative mechanisms, including small molecules and gene therapy approaches targeting tau and other proteins involved in neurodegeneration.

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
• [Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: HDAC
• [HSP90-Tau Disaggregation Complex Enhancement](/hypothesis/h-0f00fd75) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: HSP90AA1